# Veeva Systems

Type: Company (VEEV)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/veeva-systems
Canonical HTML page: https://getfinancebrief.com/entity/veeva-systems

## Timeline

- **2026-03-08**: Analyst Target Cuts — TD Cowen and Canaccord Genuity slash price targets citing competitive risks and valuation.
- **2026-03-05**: Market Volatility — VEEV stock surges 11% on long-term outlook before retreating on disclosure concerns.
- **2026-03-04**: Q4 Earnings Report — Veeva reports advancing income and sets a $6B revenue target for 2030.
- **2026-03-04**: Competitive Disclosure — Management reveals competitive losses in the CRM segment during the earnings call.

## Recent coverage (3 stories)

### Veeva Systems: Can the Life Sciences Cloud Leader Create Multimillionaires?
2026-03-15 00:39:59 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Veeva Systems remains a dominant force in the life sciences cloud sector, boasting a 13.6% CAGR since its 2013 IPO and a client list including 15 of the top 20 biopharma firms. While revenue growth is moderating as the company matures, its $20 billion total addressable market and high switching costs suggest significant long-term compounding potential.
Full story: https://getfinancebrief.com/story/veeva-systems-investment-analysis-2026

### Veeva Systems Faces Valuation Pressure as Analysts Slash Price Targets
2026-03-08 13:43:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Veeva Systems (VEEV) is navigating a complex post-earnings landscape as major analysts, including TD Cowen and Canaccord Genuity, significantly lower their price targets. Despite a bullish long-term revenue outlook, recent management disclosures regarding competitive losses have triggered a wave of valuation adjustments across Wall Street.
Full story: https://getfinancebrief.com/story/veeva-systems-analyst-price-target-cuts-march-2026

### Growth Stock Outlook 2026: Pharma Giants and AI Disruptors Lead Market
2026-03-04 04:11:57 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

As equity markets navigate 2026 volatility, analysts are highlighting a mix of established healthcare leaders and emerging AI infrastructure plays as top growth opportunities. Eli Lilly’s dominance in the obesity market and Nebius’s projected $7 billion revenue surge represent the diverse strategies for capturing alpha in the current cycle.
Full story: https://getfinancebrief.com/story/growth-stocks-outlook-h1-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.